Skip to content

Re-evaluation of the upper level of intake for zinc using novel molecular biomarkers of copper status

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN77377400
Enrollment
100
Registered
2007-06-12
Start date
2007-02-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decreased copper status Nutritional, Metabolic, Endocrine Nutritional deficiencies

Interventions

Each boy (25 per group) will take two zinc tablets per day (one in the morning with breakfast and one in the evening with dinner) for 120 days that will provide a total of either 0 (placebo group), 5,

Sponsors

Health Canada (Canada)
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Healthy boys 7 to 8 years of age 2. Boys not taking a mineral supplement and have not taken a mineral supplement three months prior to commencing the study 3. Boys not taking sodium fluoride or aspirin 4. Boys living in Guelph, Ontario vicinity 5. Informed consent by the caregivers of the boys 6. Assent by the boys

Exclusion criteria

Exclusion criteria: Individuals not fulfilling the above inclusion criteria.

Design outcomes

Primary

MeasureTime frame
Effects of different levels of zinc intake on copper status will be determined by measuring the following indices of copper nutriture: 1. Expression of erythrocyte copper chaperone for Cu/Zn superoxide dismutase 2. Plasma copper concentration 3. Plasma ceruloplasmin activity 4. Erythrocyte Cu/Zn superoxide dismutase activity

Secondary

MeasureTime frame
Effects of different levels of zinc intake on: 1. Height 2. Weight 3. Complete blood counts 4. Lipid profile

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026